Etiopathogenesis of Immune‐Mediated Necrotizing Myopathy: A Comprehensive Review of Recent Advances
CNS Neuroscience & Therapeutics · 2026-05 · 32 (5)
DOI: 10.1002/cns.70931 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 15.05.2026. Verfasst von Chang Gao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Key Lab of Myositis, China-Japan Friendship Hospital, Beijing, China. Hauptthemen laut MEDLINE: Muscular Diseases, Autoimmune Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Elite Medical Professionals Project of China-Japan Friendship Hospital, the National High Level Hospital Clinical Research Funding, the National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Immune‐mediated necrotizing myopathy (IMNM) is a rare autoimmune disease characterized by prominent muscle involvement and usually associated with serum autoantibodies targeting signal recognition particle (SRP) or 3‐hydroxy‐3‐methylglutaryl‐CoA reductase (HMGCR). Although the clinical manifestations, histopathological features, and disease classification of IMNM are well established, its etiopathogenesis remains incompletely understood.
Objectives
This review aims to provide an up‐to‐date overview on the pathogenesis of IMNM.
Results
Recent studies have implicated genetic susceptibility, autoantibodies, aberrant activation of immune cells and inflammatory mediators, and dysregulation of regulated cell death pathways in mediating tissue damage of IMNM. Anti‐SRP and anti‐HMGCR autoantibodies are pathognomonic for IMNM, and passive transfer animal models have confirmed that these autoantibodies directly mediate muscle damage, with complement activation playing a key role in this process. Dysregulation of immune cells including macrophages, T cells, and B cells, and inflammatory cytokines such as IFN‐γ, TNF‐α, and IL‐6 contributes to the inflammatory milieu and amplifies tissue injury. Furthermore, regulated cell death is involved in IMNM pathogenesis. Necroptosis may play an important role in myofiber damage in IMNM, with expression levels of RIPK3 and MLKL correlating with muscle disease severity. Pyroptosis and ER stress‐autophagy pathways have also been reported to participate in IMNM pathogenesis.
Conclusion
IMNM is a distinct autoimmune myopathy driven by pathogenic anti‐SRP and anti‐HMGCR autoantibodies and multifaceted immune dysregulation involving immune cells, inflammatory cytokines, and multiple cell death pathways. Further elucidation of these mechanisms may facilitate the development of novel therapeutic strategies for IMNM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Key Lab of Myositis, China-Japan Friendship Hospital, Beijing, China.
ORCID-Profile: Chang Gao, Wenli Li, Qingyan Liu, Guochun Wang, Qinglin Peng
Förderung
- the Elite Medical Professionals Project of China-Japan Friendship Hospital
- the National High Level Hospital Clinical Research Funding
- the National Natural Science Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Gao, C., Li, W., Liu, Q., Wang, G., & Peng, Q. (2026). Etiopathogenesis of Immune‐Mediated Necrotizing Myopathy: A Comprehensive Review of Recent Advances. CNS Neuroscience & Therapeutics, 32(5). https://doi.org/10.1002/cns.70931
Vancouver
Gao C, Li W, Liu Q, Wang G, Peng Q. Etiopathogenesis of Immune‐Mediated Necrotizing Myopathy: A Comprehensive Review of Recent Advances. CNS Neuroscience & Therapeutics. 2026;32(5). doi:10.1002/cns.70931
BibTeX
@article{Gao2026,
author = {Gao, Chang and Li, Wenli and Liu, Qingyan and Wang, Guochun and Peng, Qinglin},
title = {Etiopathogenesis of Immune‐Mediated Necrotizing Myopathy: A Comprehensive Review of Recent Advances},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {5},
doi = {10.1002/cns.70931}
}
EUVIMED